Serum levels of carcinoembryonic antigen (CEA) in patients with bipolar disorder

Acta Neuropsychiatr. 2015 Jun;27(3):177-81. doi: 10.1017/neu.2015.5. Epub 2015 Feb 20.

Abstract

Objective: Carcinoembryonic antigen (CEA) is an oncofetal glycoprotein that is widely used as a tumour marker in adenocarcinomas. However, several non-neoplastic conditions, including acute and chronic inflammation and other inflammation-related conditions, are characterised by increased CEA concentrations. Bipolar disorder (BD) ranks seventh among the worldwide burden of non-fatal diseases. Inflammatory biomarkers have been considered as one of the main key pillars of a multifactorial approach for prediction of BD in an at-risk population. BP is accompanied by activation of inflammatory, cell-mediated and negative immunoregulatory cytokines.

Methods: We measured the levels of CEA in serum samples from 44 individuals with euthymic BP out-patients and 45 healthy controls. Patients were diagnosed according to the DSM-IV criteria. CEA was measured by an electrochemiluminescence immunoassay.

Results: The mean serum CEA concentration was 2.36±1.52 and 1.77±0.98 µg/l in patients and controls, respectively. CEA levels were significantly increased in euthymic BP patients when compared with controls (p=0.031).

Conclusions: This study suggests that CEA is increased in BD and supports a role for immune activation in the core pathological mechanisms of BP. CEA levels may be a secondary marker for diagnosing BP.

Keywords: CEA; bipolar disorder; proinflammatory cytokines.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Bipolar Disorder / blood*
  • Bipolar Disorder / immunology
  • Carcinoembryonic Antigen / blood*
  • Carcinoembryonic Antigen / immunology
  • Case-Control Studies
  • Female
  • Humans
  • Immunoassay / methods
  • Male

Substances

  • Biomarkers
  • Carcinoembryonic Antigen